Brought to you by

Spotlight Innovation licenses spinal muscular atrophy compound from Indiana University
10 Nov 2016
Executive Summary
Indiana University Research & Technology Corp. granted Spotlight Innovation Inc. exclusive global rights to develop and commercialize STL182, an oral small molecule in development for spinal muscular atrophy.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com